Vantage logo

The big cap empire strikes back

If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.

Vantage logo

Seeking alpha in PI3K inhibition

Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.